Thesis 42

XLE — long thesis

Confidence: medium · Status: executed

Thesis

LLY defensive pharma long — GLP-1/incretin franchise leader (Zepbound/Mounjaro/oral Foundayo) plus deep cardiometabolic pipeline; held as rate-shielded defensive-growth ballast. Partial profit-take was executed Aug 26 at the 10-15%+ band; remaining core managed on trail. FRESH CATALYST (Sep 24): FDA approved Onswik (insulin efsitora alfa-gobe), Lilly's once-weekly basal insulin for type 2 diabetes, and Lilly signed a $3.25B research/licensing pact with InnoCare — extending the cardiometabolic franchise and reinforcing pipeline depth. LLY +3.2% today to ~$1,188. Note: this is a product/regulatory catalyst (a currently-weak attribution category standalone) but corroborates the durable-franchise fundamental thesis rather than serving as a fresh add trigger. Offsetting overhang persists: renewed drug-pricing/Medicare scrutiny (most-favored-nation, CMS lab payment cuts). Net: franchise strengthening; hold the retained core as ballast on trail. Rule #14 (30Y >5.0%, active) bars adds above formation size on this high-multiple name.

Triggers

Entry: Already held — adopted into thesis management

Exit: Remaining core on trail — exit in full on a close 10% below the post-trim high-water mark or on a close below cost basis +5%. Do not re-trim on the original 10-15% band (already executed). Full take-profit on another 10% extension beyond the trim level. Trim on a GLP-1 franchise setback or if White House drug-pricing terms are announced with quantified material GLP-1 price cuts.

Invalidation: GLP-1 franchise setback (safety/regulatory/reimbursement or competitive displacement). Healthcare underperforms SPY for 3+ consecutive weeks. Close below recent support on volume. Rate regime turns decisively dovish, evaporating the defensive rotation bid.

Cited evidence

News

Macro